The impact of postoperative exocrine index on non-alcoholic fatty liver disease following pancreaticoduodenectomy

Masashi Tsunematsu | Takeshi Gocho | Mitsuru Yanagaki | Yoshihiro Shirai | Koichiro Haruki | Kenei Furukawa | Juno Yasuda | Shinji Onda | Taro Sakamoto | Toru Ikegami

Abstract

Background: To study exocrine function of the remnant pancreas after pancreaticoduodenectomy (PD), we propose the use of an exocrine index (PEI) that combines the volume of the remnant pancreas and the intraoperative amylase activity of the pancreatic juice. Here, we aimed to determine whether the PEI can predict non-alcoholic fatty liver disease (NAFLD) following PD.

Methods: Fifty-seven patients for whom pancreatic juice amylase activity was measured during PD were enrolled. NAFLD was defined as a liver-to-spleen attenuation ratio of $<0.9$ on plain CT 1 year following surgery. We retrospectively evaluated clinical parameters, including the PEI, to identify predictors of NAFLD.

Results: Fifty-four patients (95%) were regularly administered $1200$ mg of pancreatic lipase. NAFLD was diagnosed in 13 participants (23%) 1 year following surgery. NAFLD was associated with pancreatic ductal adenocarcinoma ($P = .006$), soft pancreas ($P = .001$), small main pancreatic duct ($P = .0008$), low remnant pancreatic volume ($P < .001$), low intraoperative amylase activity in the pancreatic juice ($P = .001$), high pancreatic fibrosis ($P = .032$), and large body weight loss ($P = .015$). The PEI was significantly lower in the participants with NAFLD than in those without ($P < .001$). The participants were then classified into tertiles of PEI: $<5 \times 10^6$, $5-25 \times 10^6$, and $>25 \times 10^6$. The prevalence of NAFLD in these groups was 53% (10/19), 11% (2/19), and 5% (1/19), respectively. In multivariable analyses, there was a significant association between NAFLD and the PEI ($P$ value for trend $= .042$).

Conclusion: The PEI, calculated using the remnant pancreatic volume and the intraoperative pancreatic juice amylase activity, predicts NAFLD development following PD.

Keywords
diabetes mellitus, exocrine index, non-alcoholic fatty liver disease, pancreatic juice, pancreaticoduodenectomy
1 | INTRODUCTION

Non-alcoholic fatty liver disease (NAFLD) is a late complication of pancreaticoduodenectomy (PD), developing in 8%–46% of patients. As the surgical techniques, perioperative management, and adjuvant chemotherapy have improved, the number of long-term survivors following PD has increased. Therefore, the potential long-term metabolic complications of the procedure are receiving greater attention. A previous study showed that hepatic steatosis following PD was associated with a shorter duration of disease-free survival associated with pancreatic ductal adenocarcinoma (PDAC).

Previous studies have sought to identify risk factors for NAFLD following PD and have shown that poor exocrine function of the remnant pancreas is a risk factor. A digestive enzyme preparation containing a pancreatic enzyme is now generally administered to patients who have undergone PD to compensate for a reduction in exocrine function and ameliorate disorders in digestion and absorption. In particular, a delayed release pancreatic lipase supplement has been shown to help prevent NAFLD following PD. Nevertheless, some patients develop NAFLD following PD even when taking such a supplement. Therefore, it is important to identify predictors of NAFLD in patients who have undergone PD and are taking pancreatic enzyme supplements.

We considered that the exocrine function of the remnant pancreas might represent a useful predictor of NAFLD in patients who undergo PD. The intraoperative amylase activity in pancreatic juice is reported to be a valuable predictor of POPF following PD. Intraoperative amylase activity in pancreatic juice negatively correlates with the severity of pancreatic fibrosis, suggesting that it is likely to reflect postoperative pancreatic exocrine function. Since the volume of the residual pancreas has also been reported to be a predictor of postoperative pancreatic exocrine dysfunction, we focused on intraoperative amylase activity and residual pancreatic volume in pancreatic juice to predict pancreatic exocrine function more accurately. Therefore, we decided to use the above two factors’ product and defined the product as PEI. In the present study, we retrospectively studied patients who underwent PD in our hospital to determine whether the PEI might represent a useful predictor of NAFLD following PD.

2 | PATIENTS AND METHODS

2.1 | Patients and intraoperative procedures

Between November 2014 and April 2020, 77 patients underwent PD because of pancreatic tumors at the Jikei University Hospital, and the amylase activity of the pancreatic juice of each was measured intraoperatively. Of these, 18 were excluded because of death within 1 year of the surgery, and data for the remaining 59 patients were studied. The study was approved by the Institutional Ethics Committee of the Jikei University School of Medicine (27-177 [8062]) and conformed to the provisions of the Declaration of Helsinki, as revised in Fortaleza, Brazil, October 2013.

In patients with PDAC or tumors with malignant potential, the pancreas was transected at the level of the portal vein and radical lymph node dissection was performed, according to the anterior artery first approach. The bile duct was dissected at the common hepatic duct. After pancreatostomy, a pancreatic stent was inserted into the pancreatic duct and pancreatic juice was collected using a 2.5-ml syringe for the intraoperative measurement of the amylase activity. An end-to-side pancreatojejunostomy was performed using either the Blumgart or Kakita method, with external stenting, according to the surgeon’s preference. Reconstruction was performed using the modified Child method, with Braun anastomosis. At the end of the procedure, two drains were placed close to the pancreatic and biliary anastomoses, and these were usually removed between postoperative days (POD) 3 and 5. Postoperative pancreatic fistula (POPF) was defined according to criteria established by the 2016 update of the International Study Group on Pancreatic Fistula, and grades B and C are defined as POPF and grade A is considered to represent biochemical leakage.

We routinely prescribed 1200 mg/day of a delayed-release pancreatic lipase supplement (LipaCreon, Eisai Co Ltd, Tokyo, Japan) after the patients became able to receive sufficient oral nutrition. If there were signs of allergy, this medication was discontinued.

2.2 | Measurement of the volume of the remnant pancreas

To facilitate earlier and more accurate detection of POPF after drain removal, routine postoperative computed tomography (CT) imaging was performed between POD 5 and 7. This was performed using a 64-slice multi-detector row CT (SOMATOM Definition AS+, Siemens, Erlangen, Germany) at our hospital. Contrast-enhanced CT was performed after a rapid bolus injection of iodinated contrast agent at 2.5-4.0 ml/s using a power injector. We imaged the arterial, portal, and venous phases at 35, 70, and 180 s, respectively. The slice thickness was 1 mm, and the reconstruction interval was 5 mm. We evaluated and measured the remnant pancreas using the portal phase images, Synapse Vincent software (Fujifilm Medical, Tokyo, Japan), and its Liver Analysis Application (Figure 1A). As the length of the remnant pancreas was traced, the software automatically contoured the remnant pancreas in each CT slice and calculated the volume of the remnant pancreas in cubic centimeters. The outlines drawn by the software for each CT slice were then made manually and corrections were made if necessary.

2.3 | Calculation of the PEI

The PEI was calculated as the product of the intraoperative amylase activity of the pancreatic juice and the residual pancreatic volume after surgery.
2.4 | Evaluation of pancreatic stump

Paraffin-embedded sections from pancreatic stump were stained with hematoxylin and eosin and reviewed by an experienced gastrointestinal pathologist who was blinded to the surgical outcome. The degree of fibrosis was assessed quantitatively by calculating the ratio of the dimension of intralobular and interlobular fat to the total area of each specimen as described in the previous report.11

2.5 | Definition of NAFLD

The livers of the patients were evaluated 1 year after surgery. CT imaging was performed using the same 64-slice multi-detector row CT, with a slice thickness of 1 mm and a reconstruction interval of 5 mm. NAFLD was defined as a liver-to-spleen attenuation ratio of <0.9 on an unenhanced abdominal CT scan.6,12,14,15 We used the mean pixel density in four sectors of the liver and the median density for all the sectors of the spleen (Figure 1B). Two reviewers analyzed the CT images (MT and TG).

2.6 | Identification of risk factors for NAFLD

First, we investigated the relationships between the clinicopathologic variables of patients who underwent PD and the subsequent prevalence of NAFLD by univariate analysis. The variables included preoperative factors, intraoperative factors, postoperative factors, CT findings 1 year after surgery, and the PEI.

Next, to assess the utility of the PEI, the patients were categorized into tertiles of PEI (n = 19, each group); those with PEI ≤5 × 10^6 as a “low PEI” group, those with PEI 5-25 × 10^6 as an “intermediate PEI” group, and those with PEI <25 × 10^6 as a “high PEI” group, and multivariate ordinal logistic regression analyses were performed to evaluate the relationship between the PEI and the incidence of NAFLD. We also evaluated the relationships between the clinicopathologic variables of patients who underwent PD and diabetes mellitus (DM), a pancreatic endocrine disease, using univariate analysis, and then performed multivariate ordinal logistic regression analyses to evaluate the relationship of PEI with the incidence of DM.

2.7 | Statistical analysis

Statistical analyses were performed using STATA/SE (STATA Statistical Software, version 14.0; Stata Corp., College Station, TX, USA). Continuous variables are expressed as medians and interquartile ranges, while categorical variables are expressed as absolute numbers. Clinical datasets were compared using the Mann-Whitney U-test or chi-square test, as appropriate. Multivariate analyses were performed using the ordinal logistic regression model, and all the variables with $P < .05$ in the univariate analysis were included. A two-tailed $\alpha$ level of 0.05 was used.

3 | RESULTS

3.1 | Patient characteristics and the incidence of postoperative NAFLD

The characteristics of the 59 patients are shown in Table 1. Of these, 54 (95%) were administered 1200 mg of pancreatic lipase daily. NAFLD was diagnosed in 13 patients (23%) 1 year following surgery. The median volume of the remnant pancreas was 32 ml (range, 22-46 ml), the median intraoperative amylase activity of the pancreatic juice was 550 × 10^3 IU/L (range, 53-879 × 10^3 IU/L), and the median PEI was 16 × 10^6 (range, 2-33 × 10^6).

3.2 | Comparison of the clinicopathologic variables in patients who did or did not develop NAFLD or DM

The development of NAFLD was significantly associated with PDAC ($P = .006$), soft pancreas ($P = .001$), small main pancreatic duct ($P = .008$), low intraoperative amylase activity of the pancreatic juice ($P = .002$), and low total amylase activity of the pancreatic juice ($P = .04$).
TABLE 1 Clinicopathological factors in patients who underwent pancreatoduodenectomy (n = 57)

| Variables | Preoperative factors | Operative factors | Postoperative factors | Histopathological findings | Preoperative findings of CT images | Findings of CT images at 1 year | PEI (10^3) |
|-----------|----------------------|-------------------|-----------------------|---------------------------|----------------------------------|-------------------------------|-------------|
| Gender (male:female) | 40 (70%):17 (30%) | Pancreatic texture (soft:hard) | 36 (63%):21 (37%) | Pancreatic fibrosis (%) | 5 (0-10) | Pixel density on liver (HU) | 56.3 (49.5-62.5) |
| Age (years) | 68 (61-76) | Main pancreatic duct size (mm) | 3 (2-5) | Pancreatic intralobular fat (%) | 0 (0-10) | Pixel density on spleen (HU) | 44.7 (41.2-47.3) |
| Body weight (kg) | 59.9 (51.5-66.4) | Amylase of pancreatic juice (10^3 IU/L) | 550 (53-879) | Pancreatic interlobular fat (%) | 20 (10-55) | Pixel density ratio on liver/spleen CT | 1.3 (1.2-1.4) |
| Body mass index (kg/m^2) | 22.5 (20.4-23.7) | Duration of operation (min) | 516 (428-606) | Volume of remnant pancreas (ml) | 22 (15-30) | Pixel density on liver (HU) | 53.3 (43.8-58.2) |
| DM (yes:no) | 9 (16%):48 (84%) | Postoperative blood loss (ml) | 615 (290-1010) | Volume of remnant pancreas (ml) | 22 (15-30) | Pixel density on spleen (HU) | 45.3 (42.2-48.1) |
| Dyslipidemia (yes:no) | 4 (7%):53 (93%) | Postoperative hospital stay (days) | 26 (22-37) | Pixel density ratio on liver/spleen CT | 1.2 (1.0-1.3) | Pixel density on spleen (HU) | 45.3 (42.2-48.1) |
| Primary disease (PDAC:others) | 21 (37%):36 (63%) | POPOF (yes:no) | 18 (32%):39 (68%) | Volume of remnant pancreas (ml) | 22 (15-30) | Pixel density on liver/spleen CT | 1.2 (1.0-1.3) |
| Serum albumin level (g/dl) | 3.9 (3.6-4.4) | Adjuvant chemotherapy (yes:no) | 34 (60%):23 (40%) | Change of remnant pancreas volume | 0.67 (0.54-0.76) | Volume of remnant pancreas (ml) | 22 (15-30) |
| HDL (yes:no) | 4 (7%):53 (93%) | Prediction of incidence of NAFLD using the PEI | 36 (63%):21 (37%) | Change of remnant pancreas volume | 0.67 (0.54-0.76) | Change of remnant pancreas volume | 0.67 (0.54-0.76) |
| HbA1c, hemoglobin A1c | 34 (60%):23 (40%) | Postoperative factors | 516 (428-606) | Change of remnant pancreas volume | 0.67 (0.54-0.76) | Change of remnant pancreas volume | 0.67 (0.54-0.76) |
| HU, hounsfield unit | 54 (95%):3 (5%) | Histopathological findings | 5 (0-10) | Change of remnant pancreas volume | 0.67 (0.54-0.76) | Change of remnant pancreas volume | 0.67 (0.54-0.76) |
| NAFLD, non-alcoholic fatty liver disease | 13 (23%):4 (77%) | Preoperative factors | 40 (70%):17 (30%) | Change of remnant pancreas volume | 0.67 (0.54-0.76) | Change of remnant pancreas volume | 0.67 (0.54-0.76) |
| PDAC, pancreatic duct carcinoma | 5 (0-10) | Histopathological findings | 5 (0-10) | Change of remnant pancreas volume | 0.67 (0.54-0.76) | Change of remnant pancreas volume | 0.67 (0.54-0.76) |
| PEI, postoperative pancreatic fistula | 0 (0-10) | Preoperative findings of CT images | 20 (10-55) | Change of remnant pancreas volume | 0.67 (0.54-0.76) | Change of remnant pancreas volume | 0.67 (0.54-0.76) |
| Prediction of incidence of NAFLD using the PEI | 0 (0-10) | Findings of CT images at 1 year | 20 (10-55) | Change of remnant pancreas volume | 0.67 (0.54-0.76) | Change of remnant pancreas volume | 0.67 (0.54-0.76) |
| PEI, postoperative pancreatic fistula | 0 (0-10) | Findings of CT images at 1 year | 20 (10-55) | Change of remnant pancreas volume | 0.67 (0.54-0.76) | Change of remnant pancreas volume | 0.67 (0.54-0.76) |
| PEI, postoperative pancreatic fistula | 0 (0-10) | Findings of CT images at 1 year | 20 (10-55) | Change of remnant pancreas volume | 0.67 (0.54-0.76) | Change of remnant pancreas volume | 0.67 (0.54-0.76) |
| PEI, postoperative pancreatic fistula | 0 (0-10) | Findings of CT images at 1 year | 20 (10-55) | Change of remnant pancreas volume | 0.67 (0.54-0.76) | Change of remnant pancreas volume | 0.67 (0.54-0.76) |
| PEI, postoperative pancreatic fistula | 0 (0-10) | Findings of CT images at 1 year | 20 (10-55) | Change of remnant pancreas volume | 0.67 (0.54-0.76) | Change of remnant pancreas volume | 0.67 (0.54-0.76) |
| PEI, postoperative pancreatic fistula | 0 (0-10) | Findings of CT images at 1 year | 20 (10-55) | Change of remnant pancreas volume | 0.67 (0.54-0.76) | Change of remnant pancreas volume | 0.67 (0.54-0.76) |

Note: Continuous variables are presented as median with interquartile ranges. Categorial variables are presented as patient numbers and ratios (%).

Abbreviations: CT, computed tomography; DM, diabetes mellitus; HbA1c, hemoglobin A1c; HU, hounsfield unit; NAFLD, non-alcoholic fatty liver disease; PDAC, pancreatic duct carcinoma; PEI, postoperative exocrine index; POPOF, postoperative pancreatic fistula.

The intraoperative amylase activity of pancreatic juice is routinely measured in our hospital. It is a useful predictor of POPF following PD. The intraoperative amylase activity of pancreatic juice is routinely measured in our hospital. It is a useful predictor of POPF following PD.

The prevalence of NAFLD in the three groups was 53% (10/19) for the low PEI group, 11% (2/19) for the intermediate PEI group, and 5% (1/19) for the high PEI group, respectively (Figure 2). The pancreatic parenchyma was significantly more fibrotic in the low PEI group than in the high PEI group (Figure 3).

In the multivariable analysis, compared with the high PEI group, the odd ratios for NAFLD following PD were 1.77 (95% confidence interval [CI], 0.14-22.3) for the intermediate PEI group, and 12.5 (95% CI, 0.89-174.7) for the low PEI group (P-value for trend = .042) (Table 4). There was no significant association between incident DM and the PEI in patients who underwent PD (P-value for trend = .588).

4 | DISCUSSION

In the present study, the incidence of NAFLD 1 year after PD was 22.8% and 1200 mg/day of delayed-release pancreatic lipase supplement was being administered postoperatively by 95% of the patients. Ordinal logistic regression analysis revealed a relationship of PEI with incident NAFLD, but there was no relationship of PEI with DM.

The etiology of NAFLD following PD is thought to involve impairments in digestion, absorption, nutrition, and/or pancreatic exocrine function, and several studies have shown that a small remnant pancreas is also a predisposing factor. The volume of the remnant pancreas is considered to be a good indicator of pancreatic exocrine function and, in the present study, the volume of the remnant pancreas was significantly lower in patients with NAFLD than in those without. However, the method of measuring the remnant pancreatic volume has not been standardized.

Here, we used CT images 5-7 days after PD and Synapse Vincent software to measure the volume.
| Variables                                  | NAFLD (n = 13) | Non-NAFLD (n = 44) | P-value |
|--------------------------------------------|----------------|--------------------|---------|
| **Preoperative factors**                   |                |                    |         |
| Gender (male:female)                       | 7 (54%):6 (46%)| 33 (75%):11 (25%)  | .143    |
| Age (years)                                | 67 (62-76)     | 71 (60-76)         | .775    |
| Body weight (kg)                           | 60 (52.8-64)   | 59.5 (50.5-67.1)   | .754    |
| Body mass index (kg/m²)                    | 22 (22-24)     | 22 (20-24)         | .582    |
| DM (yes:no)                                | 1 (8%):12 (92%)| 8 (18%):36 (82%)   | .362    |
| Dyslipidemia (yes:no)                      | 1 (8%):12 (92%)| 3 (7%):41 (93%)    | .914    |
| Primary disease (PDAC:others)              | 9 (69%):4 (31%)| 12 (27%):32 (73%)  | .006    |
| Serum albumin level (g/dl)                 | 3.8 (3.6-4.6)  | 3.9 (3.5-4.4)      | .555    |
| Serum HbA1c (%)                            | 6.1 (6.0-6.2)  | 5.9 (5.5-6.6)      | .390    |
| **Operative factors**                      |                |                    |         |
| Pancreatic texture (soft:hard)             | 3 (23%):10 (77%)| 33 (75%):11 (25%)  | .001    |
| Main pancreatic duct size (mm)             | 4 (3-6)        | 2 (2-4)            | .008    |
| Amylase, pancreatic juice (10³ IU/L)       | 7 (2-434)      | 682 (227-895)      | .001    |
| Duration of operation (min)                | 578 (469-626)  | 514 (426-595)      | .238    |
| Intraoperative blood loss (ml)              | 725 (305-1235) | 565 (270-944)      | .274    |
| **Postoperative factors**                  |                |                    |         |
| Volume of remnant pancreas (ml)            | 22 (15-25)     | 41 (26-48)         | <.001   |
| POPF (yes:no)                              | 2 (15%):11 (85%)| 16 (36%):28 (64%)  | .153    |
| Postoperative hospital stay (days)          | 23 (19-38)     | 28 (23-37)         | .321    |
| Adjuvant chemotherapy (yes:no)             | 9 (69%):4 (31%)| 25 (57%):19 (43%)  | .423    |
| Pancrelipase (yes:no)                      | 11 (85%):2 (15%)| 43 (98%):1 (2%)    | .063    |
| Body weight at 1 year (kg)                 | 46.3 (42-55)   | 54.4 (45.5-61.7)   | .061    |
| Body weight ratio on post/pre              | 0.82 (0.74-0.89)| 0.93 (0.85-0.98)  | .015    |
| Serum HbA1c at 1 year (%)                  | 5.6 (5-6.2)    | 5.9 (5.3-6.4)      | .246    |
| DM at 1 year (yes:no)                      | 4 (31%):9 (69%)| 13 (30%):31 (70%)  | .932    |
| **Histopathological findings**             |                |                    |         |
| Pancreatic fibrosis (%)                     | 5 (5-10)       | 0 (0-10)           | .032    |
| Pancreatic intralobular fat (%)             | 0 (0-10)       | 0 (0-10)           | .934    |
| Pancreatic interlobular fat (%)             | 20 (10-58)     | 30 (15-60)         | .715    |
| **Preoperative findings of CT images**      |                |                    |         |
| Pixel density on liver CT (HU)             | 60 (50.5-62.5) | 56.2 (49.3-62.3)   | .634    |
| Pixel density on spleen CT (HU)            | 45.4 (41.2-46.8)| 44.2 (41.1-47.4)  | .947    |
| Pixel density ratio on liver/spleen CT      | 1.3 (1.1-1.4)  | 1.3 (1.2-1.4)      | .790    |
| **Findings of CT images at 1 year**         |                |                    |         |
| Pixel density on liver CT (HU)             | 23 (8-39)      | 57 (51-59)         | <.001   |
| Pixel density on spleen CT (HU)            | 45 (43-47)     | 45 (42-48)         | .909    |
| Pixel density ratio on liver/spleen CT      | 0.6 (0.2-0.9)  | 1.2 (1.1-1.3)      | <.001   |
| Volume of remnant pancreas (ml)            | 20 (12-26)     | 23 (17-30)         | .147    |
| Change of remnant pancreas volume          | 0.88 (0.66-1)  | 0.62 (0.51-0.82)   | .043    |
| PEI (10⁶)                                  | 0.1 (0.04-10)  | 24 (7-56)          | <.001   |

**Note:** Continuous variables are presented as median with interquartile ranges. Categorial variables are presented as patient numbers and ratios (%). Abbreviations: CT, computed tomography; DM, diabetes mellitus; HbA1c, hemoglobin A1c; HU, Hounsfield unit; NAFLD, non-alcoholic fatty liver disease; PDAC, pancreatic duct carcinoma; PEI, postoperative exocrine index; POPF, postoperative pancreatic fistula.
### TABLE 3
Comparison of the clinicopathological factors according to the positive DM in patients who underwent pancreateoduodenectomy (n = 57)

| Variables                                      | DM (n = 17) | Non-DM (n = 40) | P-value |
|------------------------------------------------|-------------|-----------------|---------|
| **Preoperative factors**                       |             |                 |         |
| Gender (male:female)                           | 13 (76%):4 (24%) | 27 (68%):13 (33%) | .498    |
| Age (years)                                    | 68 (59-77) | 70 (61-76)      | .855    |
| Body weight (kg)                               | 64 (52.6-67.1) | 58.2 (50.5-64.8) | .407    |
| Body mass index (kg/m²)                        | 22 (21-23) | 23 (20-24)      | .827    |
| DM (yes:no)                                    | 7 (41%):10 (59%) | 2 (5%):38 (95%)  | .001    |
| Dyslipidemia (yes:no)                          | 14 (82%):3 (18%) | 39 (98%):1 (3%)  | .041    |
| Primary disease (PDAC:others)                  | 9 (53%):8 (47%) | 18 (45%):22 (55%) | .583    |
| Serum albumin (g/dl)                           | 4.1 (3.3-4.5) | 3.8 (3.6-4.3)   | .720    |
| Serum HbA1c level (%)                          | 6.4 (6-8) | 5.8 (5.5-6.2)   | .003    |
| **Operative factors**                          |             |                 |         |
| Pancreatic texture (soft:hard)                 | 7 (41%):10 (59%) | 14 (35%):26 (65%) | .658    |
| Main pancreatic duct size (mm)                 | 5 (2-7) | 3 (2-4)         | .024    |
| Amylase, pancreatic juice (10^3 IU/L)          | 7 (2-434) | 710 (46-885)    | .045    |
| Duration of operation (min)                    | 520 (425-572) | 516 (443-620)   | .398    |
| Intraoperative blood loss (ml)                  | 670 (445-1055) | 530 (260-1030)  | .303    |
| **Postoperative factors**                      |             |                 |         |
| POPF (yes:no)                                  | 6 (35%):11 (65%) | 12 (30%):28 (70%) | .694    |
| Volume of remnant pancreas (ml)                | 26 (22-45) | 36 (22-47)      | .172    |
| Postoperative hospital stay (days)              | 23 (19-33) | 28 (23-38)      | .190    |
| Adjuvant chemotherapy (yes:no)                  | 10 (59%):7 (41%) | 24 (60%):16 (40%) | .934    |
| Pancrelipase (yes:no)                          | 16 (94%):1 (6%) | 39 (98%):1 (3%)  | .525    |
| Body weight at 1 year (kg)                     | 54.7 (47.2-62.5) | 53.7 (43.1-60)  | .360    |
| Body weight ratio on post/pre                  | 0.91 (0.86-0.97) | 0.9 (0.82-0.98) | .542    |
| Serum HbA1c at 1 year (%)                      | 7.1 (6.4-8.2) | 5.4 (5.1-5.9)   | <.001   |
| NAFLD at 1 year (yes:no)                       | 4 (24%):13 (76%) | 9 (23%):31 (78%) | .932    |
| **Histopathological findings**                 |             |                 |         |
| Pancreatic fibrosis (%)                        | 5 (0-10) | 5 (0-10)        | .204    |
| Pancreatic intralobular fat (%)                | 0 (0-10) | 0 (0-10)        | .567    |
| Pancreatic interlobular fat (%)                | 30 (20-95) | 20 (10-48)      | .125    |
| **Preoperative findings of CT images**         |             |                 |         |
| Pixel density on liver CT (HU)                 | 54.8 (46.4-62.1) | 56.6 (50.8-62.5) | .307    |
| Pixel density on spleen CT (HU)                | 45.8 (42.9-46.6) | 43.6 (41-47.4)  | .253    |
| Pixel density ratio on liver/spleen CT         | 1.2 (1.1-1.3) | 1.3 (1.2-1.4)   | .029    |
| **Findings of CT images at 1 year**            |             |                 |         |
| Pixel density on liver CT (HU)                 | 56 (46-60) | 52 (42-58)      | .147    |
| Pixel density on spleen CT (HU)                | 46 (43-49) | 45 (42-48)      | .412    |
| Pixel density ratio on liver/spleen CT         | 1.2 (1.0-1.3) | 1.1 (1.0-1.3)   | .264    |
| Volume of remnant pancreas (ml)                | 22 (16-27) | 22 (15-29)      | .936    |
| Change of remnant pancreas volume              | 0.9 (0.59-0.98) | 0.64 (0.5-0.79) | .063    |
| PEI (10^6)                                     | 6 (1-18) | 24 (2-47)       | .078    |

Note: Continuous variables are presented as median with interquartile ranges. Categorical variables are presented as patient numbers and ratios (%).
Abbreviations: CT, computed tomography; DM, diabetes mellitus; HbA1c, hemoglobin A1c; HU, Hounsfield unit; NAFLD, non-alcoholic fatty liver disease; PDAC, pancreatic duct carcinoma; PEI, postoperative exocrine index; POPF, postoperative pancreatic fistula.
Therefore, it is likely to reflect postoperative pancreatic exocrine function. The PEI is calculated as the product of the volume of the remnant pancreas and the intraoperative amylase activity of pancreatic juice and could therefore represent a predictor of subsequent exocrine function.

In the present study, 54 (95%) patients took the recommended dose (1200 mg) of daily pancreatic lipase. However, the dosage of pancreatic lipase was not assessed in the present study, and it is unclear if the dosage of the pancreatic lipase supplement could be safely adjusted based on PEI. Further study should be conducted to assess the optimal doses of pancreatic lipase for each patient.

A previous report used a pixel density of the remnant pancreas as an indicator of exocrine function. Although the pixel density of the remnant pancreas was considered to have the same significance as the intraoperative amylase activity of pancreatic juice according to the pathological evaluation, we adopted the intraoperative amylase activity because it does not cause measurement errors.

In the present study, the patients were categorized according to tertile of PEI to assess its utility, and in this way, we showed that PEI could predict NAFLD, but, in fact, PEI did not reflect postoperative pancreatic endocrine function. In a previous study, the remnant pancreatic volume was found to be a significant risk factor for DM, but this relationship was stronger in patients who underwent DP, rather than PD. Another study showed that obstructive pancreatitis caused by periamillary PDAC exacerbates glucose intolerance by inhibiting insulin secretion and that treatment of the periamillary tumor by pancreatectomy sometimes permits the recovery of the function of the remnant pancreas by removing the obstruction. However, the endocrine function of patients following PD cannot be explained by the remnant pancreas volume alone. Moreover, the homeostasis model assessment for insulin resistance was reported not to significantly differ between patients with NAFLD and those without. Thus, insulin resistance does not seem to be related to development of NAFLD following PD but may be involved in the progression of NAFLD to non-alcoholic steatohepatitis or beyond.

The present study had two limitations. First, it was a retrospective study conducted in a single institution with a relatively small sample size.

**TABLE 4** Ordinal logistic regression analysis to assess the association of PEI in relation to NAFLD and new onset of DM after pancreatoduodenectomy (n = 57)

| PEI          | Univariate | Multivariate |
|--------------|------------|--------------|
|              | Odds ratio | 95% CI       | Odds ratio | 95% CI       |
| NAFLD        |            |              |            |              |
| High         | 1 (reference) | 1 (reference) |
| Intermediate | 2.11       | 0.18-25.5    | 1.77       | 0.14-22.3    |
| Low          | 20.0       | 2.20-181.6   | 12.5       | 0.89-174.7   |
| P-value for trend | .002       | .042         |
| New onset of DM |          |              |            |              |
| High         | 1 (reference) | 1 (reference) |
| Intermediate | 3.04       | 0.51-18.1    | 2.40       | 0.44-12.9    |
| Low          | 1.59       | 0.23-10.8    | 1.56       | 0.16-15.4    |
| P-value for trend | .670       | .588         |

Abbreviations: CI, confidence interval; DM, diabetes mellitus; NAFLD, non-alcoholic fatty liver disease; PEI, postoperative exocrine index.
number of participants. Second, due to its small sample size, it was unable to determine an optimal cutoff value for PEI, and it was also difficult to identify the correlation between PEI and pathological findings, so we focused on the usefulness of PEI for patients who underwent PD. Therefore, large-scale prospective studies should be conducted for further clarification.

In conclusion, the PEI, which is a combination of the volume of the remnant pancreas with the intraoperative amylase activity of the pancreatic juice, may be a useful means of predicting the development of NAFLD following PD.

ACKNOWLEDGEMENTS
We thank Mark Cleasby, PhD, from Edanz (https://jp.edanz.com/ac) for editing a draft of this manuscript.

DISCLOSURE
Funding: This research was supported by a Uehara Memorial Foundation Research Grant.
Conflict of Interest: The authors declare no conflicts of interest for this article.
Approval of the Research Protocol: The protocol for this research project has been approved by a suitably constituted Ethics Committee of the institution and it conforms to the provisions of the Declaration of Helsinki. Committee of The Jikei University School of Medicine Approval no. 27-177 (8062).
Informed Consent: All informed consent was obtained from the subject(s) and/or guardian(s).
Registry and the Registration no. of the study/trial: N/A.
Animal Studies: N/A.

ORCID
Takeshi Gocho  https://orcid.org/0000-0002-8463-905X
Yoshihiro Shirai  https://orcid.org/0000-0002-4907-0101
Koichiro Haruki  https://orcid.org/0000-0002-1686-3228
Kenei Furukawa  https://orcid.org/0000-0002-5081-6417
Toru Ikekami  https://orcid.org/0000-0001-5792-5045

REFERENCES
1. Sato T, Matsuo Y, Shiga K, Morimoto M, Miyai H, Takeyama H. Factors that predict the occurrence of and recovery from nonalcoholic fatty liver disease after pancreaticoduodenectomy. Surgery. 2016;160:318–30.
2. Okabe H, Yamashita YI, Inoue R, Kinoshita S, Itoyama R, Yusa T, et al. Postoperative nonalcoholic fatty liver disease is correlated with malnutrition leading to an unfavorable clinical course for pancreatic cancer patients undergoing pancreaticoduodenectomy. Surg Today. 2020;50:193–9.
3. Song SC, Choi SH, Choi DW, Heo JS, Kim WS, Kim MJ. Potential risk factors for nonalcoholic steatohepatitis related to pancreatic secretions following pancreaticoduodenectomy. World J Gastroenterol. 2011;17:3716–23.
4. Sato R, Kishiwada M, Kuriyama N, Azumi Y, Mizuno S, Usui M, et al. Paradoxical impact of the remnant pancreatic volume and infectious complications on the development of nonalcoholic fatty liver disease after pancreaticoduodenectomy. J Hepatobiliary Pancreat Sci. 2014;21:562–72.
5. Kato H, Isaji S, Azumi Y, Kishiwada M, Hamada T, Mizuno S, et al. Development of nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH) after pancreaticoduodenectomy: proposal of a postoperative NAFLD scoring system. J Hepatobiliary Pancreat Sci. 2010;17:296–304.
6. Tanaka N, Horuchi A, Yokoyama T, Kaneko G, Horigome N, Yamura T, et al. Clinical characteristics of de novo nonalcoholic fatty liver disease following pancreaticoduodenectomy. J Gastroenterol. 2011;46:758–68.
7. Okamura Y, Sugimoto H, Yamada S, Fujii T, Nomoto S, Takeda S, et al. Risk factors for hepatic steatosis after pancreatectomy: a retrospective observational cohort study of the importance of nutritional management. Pancreas. 2012;41:1067–72.
8. Kishi Y, Shimada K, Nara S, Esaki M, Kosuge T. Administration of pancreatic juice as effective treatment for hepatic steatosis after pancreatectomy. Pancreas. 2015;44:983–7.
9. Whitcomb DC, Lehman GA, Vasileva G, Malecka-Panas E, Gubergrits N, Shen Y, et al. Pancrelipase delayed-release capsules (CREON) for exocrine pancreatic insufficiency due to chronic pancreatitis or pancreatic surgery: a double-blind randomized trial. Am J Gastroenterol. 2010;105:2276–86.
10. Furukawa K, Gocho T, Shirai Y, Iwase R, Haruki K, Fujiwara Y, et al. The decline of amylase level of pancreatic juice after pancreaticoduodenectomy predicts postoperative pancreatic fistula. Pancreas. 2016;45:1474–7.
11. Furukawa K, Gocho T, Sakamoto T, Tsunematsu M, Haruki K, Horuchi T, et al. Intraoperative amylase level of pancreatic juice as a simple predictor of pancreatic fistula after pancreaticoduodenectomy. Pancreateology. 2021;21:299–305.
12. Maehira H, Iida H, Maekawa T, Yasukawa D, Mori H, Takebayashi K, et al. Estimated functional remnant pancreatic volume predicts nonalcoholic fatty liver disease after pancreaticoduodenectomy: use of computed tomography attenuation value of the pancreas. HPB (Oxford). 2021;23:802–11.
13. Bassi C, Marchegiani G, Dervenis C, Sarr M, Abu Hilal M, Adham M, et al. International Study Group on Pancreatic Surgery (ISGPS). The 2016 update of the International Study Group (ISGPS) definition and grading of postoperative pancreatic fistula: 11 Years After. Surgery. 2017;161:584–91.
14. Fujii Y, Nanashima A, Hiyoishi M, Imamura N, Yano K, Hamada T. Risk factors for development of nonalcoholic fatty liver disease after pancreatectomy. Ann Gastroenterol Surg. 2017;1:226–31.
15. Nakagawa N, Murakami Y, Uemura K, Sudo T, Hashimoto Y, Kondo N, et al. Nonalcoholic fatty liver disease after pancreatectomy is closely associated with postoperative pancreatic exocrine insufficiency. J Surg Oncol. 2014;110:720–6.
16. Yamada D, Takahashi H, Asukai K, Hasegawa S, Wada H, Matsuda C, et al. Investigation of the influence of pancreatic surgery on new-onset and persistent diabetes mellitus. Ann Gastroenterol Surg. 2021;5:575–4.
17. Park SY, Park KM, Shin WY, Choe YM, Hur YS, Lee KY, et al. Functional and morphological evolution of remnant pancreas after resection for pancreatic adenocarcinoma. Medicine (Baltimore). 2017;96:e7495.

How to cite this article: Tsunematsu M, Gocho T, Yanagaki M, Shirai Y, Haruki K, Furukawa K, et al. The impact of postoperative exocrine index on non-alcoholic fatty liver disease following pancreaticoduodenectomy. Ann Gastroenterol Surg. 2022;6:704–711. doi:10.1002/ags3.12572